Invitation to SCI’s Free Public Evening Lecture:
Dr David Brown – Medical Researcher
What Individuals Can Do to Achieve Healthy Ageing
Wednesday 25 September 2019
- Between 2000 and 2050, the proportion of the world's population over 60 years will double from about 11% to 22%.
- The number of people aged 80 years or older will have almost quadrupled between 2000 and 2050 to 395 million worldwide.
As lifespans steadily increase, maintaining health during later years (‘healthspan’) is becoming an area of intensive research. However, to date, no convincing and safe ‘healthspan drugs’ have been approved, and when they do finally appear, their registration will be based on limited numbers in clinical trials: it will take many years to collect convincing evidence of their long-term efficacy and safety in the wider population. Therefore, waiting for the ‘healthspan’ drugs is a poor option at present for all of us.
During his Public Evening Lecture on Wednesday 25 September 2019, Dr David Brown will summarise the latest evidence on lifestyle interventions we can undertake in this age of longevity. There is abundant scientific evidence in favour of interventions we can all make to extend our healthy years, including evidence on how our lifestyle can protect DNA function, improve clearance of damaged goods from the body, reduce cognitive decline, reduce incidence of cancer - and even ways to protect the body from collateral damage if treatment for cancer becomes necessary. Find out how diet, exercise, sleep and how we use our mind all have a huge influence at this free evening lecture.
About the speaker
Dr David Brown is a medical researcher with over 40 years’ experience in the pharmaceutical / biotechnology industry both in research and in senior executive roles. He served with four of the top ten pharmaceutical companies: Zeneca, Pfizer, GlaxoWellcome, and Hoffman La-Roche.
Whilst at Pfizer he was named co-inventor on the patent for Viagra, and for eight years he led the team that invented and developed Viagra through to proof of clinical efficacy in male impotence. The drug is also marketed for treatment of pulmonary hypertension under the trade name Revatio. He also had a pivotal role in the discovery of Relpax, a treatment for migraine. Together these three drugs have achieved sales of nearly $40 billion. While at Roche in Switzerland, he was a Director of the company and, as Global Head of Drug Discovery, he had responsibility for productivity of over 2000 scientists at Roche’s five research sites in the USA, Europe and Asia.
Based in Cambridge UK, David subsequently co-founded antibody company Crescendo Biologics and also Healx Ltd (currently Chair of the board and CSO) which uses AI/ Machine Learning to find new treatments for children and adults with untreated rare diseases. He also serves on the board of ProFactor Pharma Ltd, Edinburgh (Chair), and Babraham Institute Enterprise Ltd, Cambridge (Chair). His personal research interests include anti-ageing, antibiotic resistance and reducing death rates from septic shock which has afflicted his own family.
Date for your diary: Wednesday 25 September 2019
Venue: SCI HQ, 15 Belgrave Square, London SW1X 8PS
Reception opens at 18.00 and the lecture starts at 18.30. This is a free event.
Registration will open soon...
NOTES TO EDITORS
About SCI: where science meets business
The Society of Chemical industry (SCI) is a learned society, established in 1881 specifically to promote the application of science into industry for the benefit of the public. SCI’s founders were scientists, inventors, and entrepreneurs who went on to form industrial businesses at the heart of the 20th Century Industrial Revolution. The society is unique, being a multi-science, multi-disciplinary, and international community. SCI today continues to work at the interface between science and industry, conducting a range of activities that focus on supporting innovation and the commercialisation of science.